Lyumjev – a fully closed loop case study with oref1
When Lyumjev, or URLi was announced, and pharmacodynamic details released back in September 2019, I noted that it had the potential to transform the use […]
Faster Insulin
Clinical benefits of faster insulins – an n=1 answer to a common #EASD2020 question
Whilst watching EASD2020 this week, during the session on developing better insulins, a question was asked by multiple participants in relation to faster insulins. This […]
Ultra-Rapid Lispro: What is it and why is it interesting?
In the second article in this series looking at ultra-rapid insulin, we talk about Lilly’s new kid on the block: Ultra-Rapid Lispro (URLi) Ultra-Rapid Lispro […]
Enough is enough. I can’t go on…. Details of the EMA Submission Fiasp CSII study
Harking back to a disco classic, I have to put my hands up and admit that I’ve reached the end of my tether with Fiasp […]
Defining an “Artificial Pancreas”. Where are we with DIY systems? #WeAreNotWaiting
Back in 2013, in the US, Medtronic launched the 530G pump, and everyone and his dog called it an artificial pancreas. As Scott Hanselmann stated […]
A graphical look at my #Fiasp failure. Does it show anything new?
Whilst I was more or less forced to swap off Fiasp a week or so ago, I thought it might be interesting to take a […]
Does #Fiasp equal Freedom? A round up of collective experiences
As I’ve mentioned plenty of times, I’ve been using Fiasp in a Closed Loop for some time, and the last week or so has really […]
#Fiasp two months on. Bedded in and settled down – what did I change to get there?
I’ve been using Fiasp now for two months, and as discussed in the various items I’ve written, the first month proved to be a fairly […]